MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

26.49 -2.29

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

26.1

Max

26.8

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5.8M 40M
Pardavimai	16M 200M
P/E Sektoriaus vid.	8.577 37.257
Pelnas, tenkantis vienai akcijai	0.92
Pelno marža	19.839
Darbuotojai	268
EBITDA	3M 59M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+65.85% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-10-28

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-511M 1.5B
Ankstesnė atidarymo kaina	28.78
Ankstesnė uždarymo kaina	26.49

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-08 20:45; UTC

Uždarbis

Costco Wholesale Sales Climb in September, Early October

2025-10-08 20:12; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

TaskUs Shares Fall After Holders Reject Take-Private Deal

2025-10-08 16:39; UTC

Pagrindinės rinkos jėgos

Mining Shares Rise as Gold Prices Soar

2025-10-08 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2025-10-08 23:43; UTC

Rinkos pokalbiai

Gold Falls on Possible Profit-Taking -- Market Talk

2025-10-08 23:18; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics to Finance Acquisition Using Internal Funds

2025-10-08 23:17; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

2025-10-08 23:16; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

2025-10-08 21:54; UTC

Rinkos pokalbiai

Uždarbis

James Hardie Could Beat Annual Earnings Goal -- Market Talk

2025-10-08 21:30; UTC

Rinkos pokalbiai

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

2025-10-08 21:26; UTC

Rinkos pokalbiai

Uždarbis

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

2025-10-08 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-08 19:15; UTC

Rinkos pokalbiai

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

2025-10-08 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

2025-10-08 18:47; UTC

Rinkos pokalbiai

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

2025-10-08 18:46; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

2025-10-08 18:46; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs Will Remain a Publicly Traded Co >TASK

2025-10-08 18:46; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

2025-10-08 18:45; UTC

Įsigijimai, susijungimai, perėmimai

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

2025-10-08 18:07; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Edging Up in September -- Market Talk

2025-10-08 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-10-08 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-10-08 15:57; UTC

Rinkos pokalbiai

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

2025-10-08 15:56; UTC

Rinkos pokalbiai

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

2025-10-08 15:53; UTC

Rinkos pokalbiai

Argentine Sovereign Debt Seen as Attractive -- Market Talk

2025-10-08 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

2025-10-08 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

2025-10-08 15:43; UTC

Įsigijimai, susijungimai, perėmimai

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

2025-10-08 15:42; UTC

Įsigijimai, susijungimai, perėmimai

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

65.85% į viršų

12 mėnesių prognozė

Vidutinis 44.1 USD 65.85%

Aukščiausias 62 USD

Žemiausias 31 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.